Pancreatic cancer immunotherapy using a
tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells

Tanida,Tsukasa; Tanemura,Masahiro; Miyoshi,Eiji; Nagano,Hiroaki; Furukawa,Kenta; Nonaka,Yuji; Akita,Hirofumi; Hama,Naoki; Wada,Hiroshi; Kawamoto,Koichi; Kobayashi,Shogo; Eguchi,Hidetoshi; Mori,Masaki; Doki,Yuichiro

doi:10.3892/ijo.2014.2717

Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells

Authors:
- Tsukasa Tanida
- Masahiro Tanemura
- Eiji Miyoshi
- Hiroaki Nagano
- Kenta Furukawa
- Yuji Nonaka
- Hirofumi Akita
- Naoki Hama
- Hiroshi Wada
- Koichi Kawamoto
- Shogo Kobayashi
- Hidetoshi Eguchi
- Masaki Mori
- Yuichiro Doki
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
Published online on: October 21, 2014 https://doi.org/10.3892/ijo.2014.2717
Pages: 78-90

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is a lethal disease that remains one of the most resistant to traditional therapies. Immunotherapy in pancreatic cancer induces the recruitment and activation of T cells that recognize tumor-associated antigens (TAAs); thus, the mechanism differs from that of chemotherapy and radiotherapy. The goal of cancer immunotherapy is to elicit immune responses against autologous tumors, and especially to induce multiple T cell clones against a variety of TAAs. In the present study, we prepared a polyvalent tumor lysate vaccine engineered to express the α-gal epitopes, Galα1-3Galβ1-4 GlcNAc-R (i.e., α-gal tumor lysate), from primary tumors. The vaccine elicited strong antibody production against multiple TAAs in pancreatic cancer cells and induced activation of multiple tumor-specific T cells in α1,3-galactosyltransferase (α1,3GT) knockout (KO) mice. The tumor lysate vaccine exhibited a similar effect on pancreatic cancer stem cells (CSCs) with the CD44+CD24+ phenotype. Furthermore, in vivo experiments using NOD/SCID mice, inoculated with splenocytes from KO mice vaccinated with the α-gal tumor lysate and injected with pancreatic cancer cells, showed successful induction of a marked immune response that resulted in suppression of tumorigenesis and significant improvement in overall survival. In contrast, inoculation of lymphocytes from KO mice vaccinated with control tumor lysate vaccine had no effects on tumor growth and survival. The results of both in vitro and in vivo experiments emphasize the efficiency of tumor lysate vaccines expressing α-gal epitopes in targeting all pancreatic cancer cells, including differentiated cancer cells and pancreatic CSCs. The α-gal tumor lysate vaccine could be the basis for a novel therapeutic approach in human clinical trials.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Lepisto AJ, Moser AJ, Zeh H, et al: A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6:955–964. 2008.PubMed/NCBI
3	Gjertsen MK, Bakka A, Breivik J, et al: Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet. 346:1399–1400. 1995. View Article : Google Scholar : PubMed/NCBI
4	Laheru D and Jaffee EM: Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 5:459–467. 2005. View Article : Google Scholar : PubMed/NCBI
5	Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 7:3862–3868. 2001.PubMed/NCBI
6	Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
7	Soares KC, Zheng L, Edil B and Jaffee EM: Vaccines for pancreatic cancer. Cancer J. 18:642–652. 2012. View Article : Google Scholar
8	Galili U, Clark MR, Shohet SB, Buehler J and Macher BA: Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1→3Gal epitope in primates. Proc Natl Acad Sci USA. 84:1369–1373. 1987. View Article : Google Scholar : PubMed/NCBI
9	Tanemura M, Yin D, Chong AS and Galili U: Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest. 105:301–310. 2000. View Article : Google Scholar : PubMed/NCBI
10	Tanemura M, Saga A, Kawamoto K, et al: In vitro and in vivo prevention of human CD8⁺ CTL-mediated xenocytotoxicity by pig c-FLIP expression in porcine endothelial cells. Am J Transplant. 8:288–297. 2008. View Article : Google Scholar
11	Galili U and LaTemple DC: Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today. 18:281–285. 1997. View Article : Google Scholar : PubMed/NCBI
12	Deguchi T, Tanemura M, Miyoshi E, et al: Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res. 70:5259–5269. 2010. View Article : Google Scholar : PubMed/NCBI
13	Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
14	Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI
15	LaTemple DC and Galili U: Adult and neonatal anti-Gal response in knock-out mice for alpha1,3-galactosyltransferase. Xenotransplantation. 5:191–196. 1998. View Article : Google Scholar : PubMed/NCBI
16	Thall AD, Maly P and Lowe JB: Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem. 270:21437–21440. 1995. View Article : Google Scholar : PubMed/NCBI
17	Sipos B, Moser S, Kalthoff H, Torok V, Lohr M and Kloppel G: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 442:444–452. 2003.PubMed/NCBI
18	LaTemple DC, Henion TR, Anaraki F and Galili U: Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res. 56:3069–3074. 1996.PubMed/NCBI
19	Tanemura M, Maruyama S and Galili U: Differential expression of alpha-GAL epitopes (Galalpha1–3Galbeta1–4GlcNAc-R) on pig and mouse organs. Transplantation. 69:187–190. 2000. View Article : Google Scholar
20	Kawamoto K, Tanemura M, Nishida T, Fukuzawa M, Ito T and Matsuda H: Significant inhibition of human CD8(+) cytotoxic T lymphocyte-mediated xenocytotoxicity by overexpression of the human decoy Fas antigen. Transplantation. 81:789–796. 2006. View Article : Google Scholar : PubMed/NCBI
21	LaTemple DC, Abrams JT, Zhang SY and Galili U: Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3-galactosyltransferase. Cancer Res. 59:3417–3423. 1999.PubMed/NCBI
22	Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8⁺ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 200:297–306. 2004. View Article : Google Scholar
23	Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 19:145–156. 2001.
24	Hassan R and Ho M: Mesothelin targeted cancer immunotherapy. Eur J Cancer. 44:46–53. 2008. View Article : Google Scholar
25	Galili U, Chen ZC and DeGeest K: Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. Gynecol Oncol. 90:100–108. 2003. View Article : Google Scholar : PubMed/NCBI
26	Ladjemi MZ, Jacot W, Chardes T, Pelegrin A and Navarro-Teulon I: Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 59:1295–1312. 2010. View Article : Google Scholar : PubMed/NCBI
27	Tang CK, Katsara M and Apostolopoulos V: Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines. 7:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
28	Liu JP, Chen W, Schwarer AP and Li H: Telomerase in cancer immunotherapy. Biochim Biophys Acta. 1805:35–42. 2010.PubMed/NCBI
29	Ryan BM, O’Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
30	Saito H, Dubsky P, Dantin C, Finn OJ, Banchereau J and Palucka AK: Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8⁺ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res. 8:R652006. View Article : Google Scholar : PubMed/NCBI
31	Schnurr M, Scholz C, Rothenfusser S, et al: Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62:2347–2352. 2002.PubMed/NCBI
32	Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J and Noll T: Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8⁺ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol. 231:112–125. 2004. View Article : Google Scholar : PubMed/NCBI
33	Palucka AK, Ueno H, Connolly J, et al: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. J Immunother. 29:545–557. 2006. View Article : Google Scholar : PubMed/NCBI
34	Fields RC, Shimizu K and Mule JJ: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 95:9482–9487. 1998. View Article : Google Scholar : PubMed/NCBI
35	Brossart P and Bevan MJ: Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood. 90:1594–1599. 1997.PubMed/NCBI
36	Shen Z, Reznikoff G, Dranoff G and Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 158:2723–2730. 1997.PubMed/NCBI
37	Shakhar G and Ben-Eliyahu S: Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 10:972–992. 2003. View Article : Google Scholar
38	Weighardt H, Heidecke CD, Emmanuilidis K, et al: Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery. 127:309–315. 2000. View Article : Google Scholar
39	Livingston P: The unfulfilled promise of melanoma vaccines. Clin Cancer Res. 7:1837–1838. 2001.PubMed/NCBI
40	Khong HT and Restifo NP: Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat Immunol. 3:999–1005. 2002. View Article : Google Scholar
41	Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
42	Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar : PubMed/NCBI
43	Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI